UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression

Nature (London), 2003-06, Vol.423 (6940), p.655-659

2003

Volltextzugriff (PDF)

Small Interfering RNAs Directed against β-Catenin Inhibit the in Vitro and in Vivo Growth of Colon Cancer Cells

Clinical cancer research, 2003-04, Vol.9 (4), p.1291-1300

2003

Volltextzugriff (PDF)

Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit

Clinical cancer research, 2004-05, Vol.10 (10), p.3333-3341

2004

Volltextzugriff (PDF)

Sulindac Enhances Tumor Necrosis Factor-α-mediated Apoptosis of Lung Cancer Cell Lines by Inhibition of Nuclear Factor-κB

Clinical cancer research, 2002-02, Vol.8 (2), p.354-360

2002

Volltextzugriff (PDF)

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

Annals of oncology, 2018-06, Vol.29, p.v110-v110

2018

Volltextzugriff (PDF)

Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil

Acta pharmacologica Sinica, 2006-10, Vol.27 (10), p.1375-1381

2006

Volltextzugriff (PDF)

When Phenotype Does Not Match Genotype—The Importance of Returning to the Raw Data

The journal of applied laboratory medicine, 2019-11, Vol.4 (3), p.446-450

2019

Volltextzugriff (PDF)

Cells lacking IKKα show nuclear cyclin D1 overexpression and a neoplastic phenotype: role of IKKα as a tumor suppressor

Molecular cancer research, 2011-03, Vol.9 (3), p.341-349

2011

Volltextzugriff (PDF)

Nuclear role of I kappa B Kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression

The Journal of biological chemistry, 2004-01, Vol.279 (5), p.3509-3515

2004

Volltextzugriff (PDF)

IκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation

The Journal of biological chemistry, 2005-10, Vol.280 (40), p.33945-33952

2005

Volltextzugriff (PDF)

Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies

American journal of clinical oncology, 2008-06, Vol.31 (3), p.219-225

2008

Volltextzugriff (PDF)

Differences in clinical outcomes in young-onset colorectal cancer based on ethnicity in an NCI designated comprehensive cancer center

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3605-3605

2019

Volltextzugriff (PDF)

Interaction between regorafenib and warfarin therapy

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.651-651

2017

Volltextzugriff (PDF)

The effects of pioglitazone treatment on pancreatic cancer-related insulin resistance

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15752-e15752

2017

Volltextzugriff (PDF)

Impact of palliative care consults on racial disparity in do-not resuscitation (DNR) orders at an urban safety net hospital

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.10027-10027

2018

Volltextzugriff (PDF)

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3504-3504

2018

Volltextzugriff (PDF)

O-030Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

Annals of oncology, 2018-06, Vol.29 (suppl_5)

2018

Volltextzugriff (PDF)

Prescribing patterns for FOLFIRINOX in the real world

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.463-463

2018

Volltextzugriff (PDF)

A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3537-3537

2015

Volltextzugriff (PDF)

Palliative care and end-of-life health care utilization of pancreatic cancer patients at an urban safety-net hospital

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.489-489

2018

Volltextzugriff (PDF)

Chemotherapy (CT) for advanced biliary tract cancers (BTC): A retrospective analysis from UT Southwestern Medical Center (UTSW) and Parkland Hospital (PH)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15200-e15200

2013

Volltextzugriff (PDF)

A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4109-4109

2015

Volltextzugriff (PDF)

Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e14649-e14649

2015

Volltextzugriff (PDF)

A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.345-345

2015

Volltextzugriff (PDF)

Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.767-767

2015

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(49)
Tagungsberichte
(1)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression

Small Interfering RNAs Directed against β-Catenin Inhibit the in Vitro and in Vivo Growth of Colon Cancer Cells

Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit

Sulindac Enhances Tumor Necrosis Factor-α-mediated Apoptosis of Lung Cancer Cell Lines by Inhibition of Nuclear Factor-κB

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil

When Phenotype Does Not Match Genotype—The Importance of Returning to the Raw Data

Cells lacking IKKα show nuclear cyclin D1 overexpression and a neoplastic phenotype: role of IKKα as a tumor suppressor

Nuclear role of I kappa B Kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression

IκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation

Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies

Differences in clinical outcomes in young-onset colorectal cancer based on ethnicity in an NCI designated comprehensive cancer center

Interaction between regorafenib and warfarin therapy

The effects of pioglitazone treatment on pancreatic cancer-related insulin resistance

Impact of palliative care consults on racial disparity in do-not resuscitation (DNR) orders at an urban safety net hospital

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

O-030Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

Prescribing patterns for FOLFIRINOX in the real world

A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma

Palliative care and end-of-life health care utilization of pancreatic cancer patients at an urban safety-net hospital

Chemotherapy (CT) for advanced biliary tract cancers (BTC): A retrospective analysis from UT Southwestern Medical Center (UTSW) and Parkland Hospital (PH)

A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)

Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC)

A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)

Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC)

Suchergebnisse filtern